Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to test a new radiotracer called 68Ga-NOTA-AE105 for
PET imaging of uPAR (urokinase plasminogen activator receptor). The tracer has the potential
of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and
less aggressive tumors. This is a first in human study to test the radiotracer in cancer
patients. The biodistribution and tumor uptake will be evaluated by repeated PET imaging (10
minutes, 1 hour and 2 hours post injection).